Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma

J Thorac Oncol. 2019 Aug;14(8):e168-e169. doi: 10.1016/j.jtho.2019.03.009.

Authors

Takamasa Nakasuka¹, Eiki Ichihara², Go Makimoto³, Yoshinobu Maeda³, Katsuyuki Kiura¹

Affiliations

¹ Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
² Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan. Electronic address: ichiha-e@md.okayama-u.ac.jp.
³ Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

PMID: 31345339
DOI: 10.1016/j.jtho.2019.03.009

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenocarcinoma of Lung / drug therapy*
Adenocarcinoma of Lung / pathology
Bevacizumab / pharmacology
Bevacizumab / therapeutic use*
Carbazoles / pharmacology
Carbazoles / therapeutic use*
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Piperidines / pharmacology
Piperidines / therapeutic use*
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use*

Substances

Carbazoles
Piperidines
Protein Kinase Inhibitors
Bevacizumab
alectinib